DUBLIN--(BUSINESS WIRE)--The "Allergic Conjunctivitis Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28% from 2022 to 2031.
An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis. The conjunctiva is a membrane that covers the interior of the eyelids and the surface of the eyeball. Allergens can irritate the conjunctiva, especially during the hay fever season. Conjunctivitis due to an allergy is extremely prevalent. It is a response by an individual's body to chemicals that it deems to be potentially dangerous.
Conjunctivitis caused by allergens is one of the most commonly occurring allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes. It's also possible to have puffy eyes when one first wake up in the morning.
The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies. According to National Centre of medicine allergic conjunctivitis or conjunctival symptoms are present in 30-71% of patients with allergic rhinitis as many people are suffering from allergic conjunctivitis demand for drugs increases.
In addition, many key market players are focusing on R&D activities to develop new drugs for the treatment of ocular allergies is a key trend of the market, which is expected to fuel the growth in the forecast period.
Furthermore, poor hygienic practices such as touching eyes with unclean hands, using contaminated makeup & lotions causes ocular allergy, which is anticipated to drive the market growth in the near future. Rise in prevalence of sexually transmitted diseases tends to drive the market growth. The most prevalent STIs are chlamydia and gonorrhoea, and both can result in conjunctivitis.
Either directly through sexual fluids like semen or when infected individuals rub their eyes after contacting infected genital areas, which are the two ways the illness enters the eye. Thus, such high number of cases are expected to boost the allergic conjunctivitis procedures.
However, unfavorable reimbursements scenarios and lack of awareness of ocular allergies are expected to hinder the growth of the market. Conversely, rapid rise in urbanization leads to more exposure to chemicals and pollutants in both developed and developing countries, which is expected to provide a great opportunity for the investors to invest in the market.
Key Benefits
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the allergic conjunctivitis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global allergic conjunctivitis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Antihistamines Mast Cell Stabilizers
- Corticosteroids
- Others
By Disease Type
- Seasonal Allergic Conjunctivitis (SAC)
- Perennial Allergic Conjunctivitis (PAC)
By Distribution Channel
- Hospital Pharmacies
- Drug stores Retail Pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- AbbVie Inc.
- Ajanta Pharma Limited
- Akron Operating Company LLC
- Alembic Pharmaceuticals Ltd.
- Bausch Health Companies Inc.
- Cipla Ltd
- Grevis Pharmaceutical Private Limited
- Indoco Remedies Ltd.
- Jabs Biotech Pvt. Ltd.
- JAWA Pharmaceuticals Pvt. Ltd.
- Johnson and Johnson
- Novartis AG
- Ocular Therapeutics, Inc.
- Santen Pharmaceuticals Co. Ltd.
- Spectra Vision Care Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/13q0ty
